{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T01:14:53Z","timestamp":1774142093657,"version":"3.50.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81973713"],"award-info":[{"award-number":["81973713"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Integrative Medicine"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.joim.2025.01.003","type":"journal-article","created":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T15:58:46Z","timestamp":1737215926000},"page":"138-144","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["An adaptive Bayesian randomized controlled trial of traditional Chinese medicine in progressive pulmonary fibrosis: Rationale and study design"],"prefix":"10.1016","volume":"23","author":[{"given":"Cheng","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-sen","family":"Nie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuan-tao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-jing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao-ran","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guang-fu","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuang-jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing-song","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shi-yan","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.joim.2025.01.003_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.disamonth.2022.101484","article-title":"Idiopathic pulmonary fibrosis: diagnosis, biomarkers and newer treatment protocols","volume":"69","author":"Patel","year":"2023","journal-title":"Dis Mon"},{"issue":"9","key":"10.1016\/j.joim.2025.01.003_b0010","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am J Respir Crit CareMed"},{"issue":"11","key":"10.1016\/j.joim.2025.01.003_b0015","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1080\/03007995.2019.1647040","article-title":"Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management","volume":"35","author":"Wijsenbeek","year":"2019","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"10.1016\/j.joim.2025.01.003_b0020","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1007\/s12325-020-01578-6","article-title":"Estimation of the prevalence of progressive fibrosing interstitial lung diseases: systematic literature review and data from a physician survey","volume":"38","author":"Olson","year":"2021","journal-title":"Adv Ther"},{"issue":"1","key":"10.1016\/j.joim.2025.01.003_b0025","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/s12931-019-1161-4","article-title":"Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat","volume":"20","author":"Maher","year":"2019","journal-title":"Respir Res"},{"issue":"10","key":"10.1016\/j.joim.2025.01.003_b0030","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1007\/s11655-017-2429-5","article-title":"Effectiveness and safety of Chinese medicine for idiopathic pulmonary fibrosis: a systematic review and meta-analysis","volume":"25","author":"Wu","year":"2019","journal-title":"Chin J Integr Med"},{"issue":"37","key":"10.1016\/j.joim.2025.01.003_b0035","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000022016","article-title":"Danhong injection in the treatment of idiopathic pulmonary fibrosis: a protocol for systematic review and meta-analysis","volume":"99","author":"Lan","year":"2020","journal-title":"Medicine (Baltimore)"},{"issue":"22","key":"10.1016\/j.joim.2025.01.003_b0040","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1001\/jama.2021.20552","article-title":"Heterogeneity of treatment effect: estimating how the effects of interventions vary across individuals","volume":"326","author":"Angus","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.joim.2025.01.003_b0045","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Adaptive designs for clinical trials of drugs and biologics: guidance for industry. (2019-11) [2023-10-01]. https:\/\/www.fda.gov\/media\/78495\/download."},{"issue":"8 Suppl","key":"10.1016\/j.joim.2025.01.003_b0050","doi-asserted-by":"crossref","first-page":"S130","DOI":"10.1016\/j.jclinepi.2013.02.015","article-title":"ESETT and ADAPT-IT Investigators. Bayesian adaptive trials offer advantages in comparative effectiveness trials: an example in status epilepticus","volume":"66","author":"Connor","year":"2013","journal-title":"J Clin Epidemiol"},{"issue":"6","key":"10.1016\/j.joim.2025.01.003_b0055","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1136\/medethics-2017-104549","article-title":"Learning health systems, clinical equipoise and the ethics of response adaptive randomisation","volume":"44","author":"London","year":"2018","journal-title":"J Med Ethics"},{"key":"10.1016\/j.joim.2025.01.003_b0060","series-title":"The theory of response-adaptive randomization in clinical trials","author":"Hu","year":"2006"},{"issue":"Suppl 1","key":"10.1016\/j.joim.2025.01.003_b0065","first-page":"S231","article-title":"An adaptive platform trial for evaluating treatments in patients with life-threatening hemorrhage from traumatic injuries: rationale and proposal","volume":"62","author":"Tolles","year":"2022","journal-title":"Transfusion"},{"issue":"1","key":"10.1016\/j.joim.2025.01.003_b0070","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1186\/s13063-019-3664-1","article-title":"Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols","volume":"20","author":"Park","year":"2019","journal-title":"Trials"},{"issue":"1","key":"10.1016\/j.joim.2025.01.003_b0075","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1056\/NEJMra1510062","article-title":"Master protocols to study multiple therapies, multiple diseases, or both","volume":"377","author":"Woodcock","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.joim.2025.01.003_b0080","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1177\/1740774520943846","article-title":"Anti-thrombotic therapy to ameliorate complications of COVID-19 (ATTACC): study design and methodology for an international, adaptive Bayesian randomized controlled trial","volume":"17","author":"Houston","year":"2020","journal-title":"Clin Trials"},{"issue":"2","key":"10.1016\/j.joim.2025.01.003_b0085","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/nur.20247","article-title":"Considerations in determining sample size for pilot studies","volume":"31","author":"Hertzog","year":"2008","journal-title":"Res Nurs Health"},{"key":"10.1016\/j.joim.2025.01.003_b0090","unstructured":"Pulmonary Disease Branch of China Association of Chinese Medicine. Diagnostic criteria for Chinese medicine syndromes of diffuse interstitial lung disease (2012 edition). Zhong Yi Za Zhi 2012;53(13):1163\u20135 [Chinese]."},{"key":"10.1016\/j.joim.2025.01.003_b0095","unstructured":"Internal Branch of China Association of Chinese Medicine, Pulmonary Disease Branch of China Medical Association of Minorities, Pulmonary Disease Branch of China Association of Chinese Medicine. Diagnostic criteria of traditional Chinese medicine syndrome differentiation for idiopathic pulmonary fibrosis (2019 edition). Zhong Yi Za Zhi 2020;61(18):1653\u20136 [Chinese]."},{"key":"10.1016\/j.joim.2025.01.003_b0100","unstructured":"Li Y. Efficacy and mechanism of San\u2019ao Decoction based on literature and information database. Nanjing: Nanjing University of Chinese Medicine; 2014 [Chinese]."},{"key":"10.1016\/j.joim.2025.01.003_b0105","unstructured":"National Pharmacopoeia Committee. Pharmacopoeia of the People\u2019s Republic of China. Beijing: China Medical Science and Technology Press; 2020 [Chinese]."},{"key":"10.1016\/j.joim.2025.01.003_b0110","unstructured":"Interstitial Lung Diseases Group of Respiratory Branch of Chinese Medical Association, Working Committee of Interstitial Lung Diseases of Respiratory Physicians Branch of Chinese Medical Association. Chinese expert consensus on the diagnosis and treatment of acute exacerbation of idiopathic pulmonary fibrosis. Zhonghua Yi Xue Za Zhi 2019;99(26):2014\u201323 [Chinese]."},{"issue":"6","key":"10.1016\/j.joim.2025.01.003_b0115","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/j.jaip.2019.01.049","article-title":"Methods of cough assessment","volume":"7","author":"Cho","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"10.1016\/j.joim.2025.01.003_b0120","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01157-2017","article-title":"Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis","volume":"50","author":"van Manen","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.joim.2025.01.003_b0125","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/978-3-540-79842-2_16","article-title":"Clinical cough IV: what is the minimal important difference for the Leicester Cough Questionnaire?","volume":"187","author":"Raj","year":"2009","journal-title":"Handb Exp Pharmacol"},{"issue":"1","key":"10.1016\/j.joim.2025.01.003_b0130","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/s12931-021-01790-0","article-title":"Validation and minimum important difference of the UCSD shortness of breath questionnaire in fibrotic interstitial lung disease","volume":"22","author":"Chen","year":"2021","journal-title":"Respir Res"},{"issue":"5","key":"10.1016\/j.joim.2025.01.003_b0135","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/j.chest.2020.04.047","article-title":"Managing fatigue in patients with interstitial lung disease","volume":"158","author":"Vivienne","year":"2020","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.joim.2025.01.003_b0140","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1348\/1359107041557048","article-title":"Measuring fatigue in sarcoidosis: the Fatigue Assessment Scale (FAS)","volume":"9","author":"De Vries","year":"2004","journal-title":"Br J Health Psychol"},{"issue":"1","key":"10.1016\/j.joim.2025.01.003_b0145","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S2213-2600(20)30330-1","article-title":"Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial","volume":"9","author":"Highland","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.joim.2025.01.003_b0150","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1186\/s13063-022-06664-4","article-title":"Optimizing a Bayesian hierarchical adaptive platform trial design for stroke patients","volume":"23","author":"Gao","year":"2022","journal-title":"Trials"},{"issue":"3","key":"10.1016\/j.joim.2025.01.003_b0155","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/bimj.200510220","article-title":"Stochastic inequality probabilities for adaptively randomized clinical trials","volume":"48","author":"Cook","year":"2006","journal-title":"Biom J"},{"issue":"2","key":"10.1016\/j.joim.2025.01.003_b0160","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/pst.1845","article-title":"Response-adaptive designs for binary responses: how to offer patient benefit while being robust to time trends?","volume":"17","author":"Villar","year":"2018","journal-title":"Pharm Stat"},{"issue":"1","key":"10.1016\/j.joim.2025.01.003_b0165","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12874-020-01042-7","article-title":"Do we need to adjust for interim analyses in a Bayesian adaptive trial design?","volume":"20","author":"Ryan","year":"2020","journal-title":"BMC Med Res Methodol"},{"issue":"24","key":"10.1016\/j.joim.2025.01.003_b0170","doi-asserted-by":"crossref","first-page":"4386","DOI":"10.1002\/sim.2869","article-title":"A covariate adjusted two-stage allocation design for binary responses in randomized clinical trials","volume":"26","author":"Bandyopadhyay","year":"2007","journal-title":"Stat Med"},{"issue":"04","key":"10.1016\/j.joim.2025.01.003_b0175","first-page":"307","article-title":"Enrichment design method and Chinese medicine clinical research","volume":"58","author":"Yan","year":"2017","journal-title":"Zhong Yi Za Zhi"},{"key":"10.1016\/j.joim.2025.01.003_b0180","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3389\/fphar.2019.00301","article-title":"Trial refresh: a case for an adaptive platform trial for pulmonary exacerbations of cystic fibrosis","volume":"10","author":"Schultz","year":"2019","journal-title":"Front Pharmacol"},{"issue":"11","key":"10.1016\/j.joim.2025.01.003_b0185","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1093\/cid\/ciaa334","article-title":"Resist the temptation of response-adaptive randomization","volume":"71","author":"Proschan","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"18","key":"10.1016\/j.joim.2025.01.003_b0190","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.joim.2025.01.003_b0195","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/sim.8414","article-title":"Optimizing interim analysis timing for Bayesian adaptive commensurate designs","volume":"39","author":"Wu","year":"2020","journal-title":"Stat Med"},{"issue":"3","key":"10.1016\/j.joim.2025.01.003_b0200","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1093\/biostatistics\/kxy009","article-title":"Bayesian clinical trial design using historical data that inform the treatment effect","volume":"20","author":"Psioda","year":"2019","journal-title":"Biostatistics"}],"container-title":["Journal of Integrative Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S209549642500007X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S209549642500007X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,13]],"date-time":"2025-04-13T01:52:43Z","timestamp":1744509163000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S209549642500007X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S209549642500007X"],"URL":"https:\/\/doi.org\/10.1016\/j.joim.2025.01.003","relation":{},"ISSN":["2095-4964"],"issn-type":[{"value":"2095-4964","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An adaptive Bayesian randomized controlled trial of traditional Chinese medicine in progressive pulmonary fibrosis: Rationale and study design","name":"articletitle","label":"Article Title"},{"value":"Journal of Integrative Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.joim.2025.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Shanghai Yueyang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}